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Updating and validating quality prescribing indicators for use in Australian 1 
general practice 2 
ABSTRACT  3 
Objective: To update and validate quality prescribing indicators (QPIs) for Australian general 4 
practice.  5 
Design and Setting: The study comprised two phases: (1) developing a preliminary list of 6 
potential QPIs based on the 2006 National Prescribing Service (NPS) MedicineWise 7 
indicators, published literature, international indicators and guidelines, and through qualitative 8 
focus group discussions; and (2) validating the proposed QPIs through a two-round online 9 
survey using the Delphi technique.  10 
Participants: The Delphi panel included four general practitioners, four pharmacists and two 11 
clinical pharmacologists. 12 
Main outcome measures: The Delphi panel rated the potential QPIs for their validity, 13 
importance and feasibility using a 1-10 Likert scale. 14 
Results: In the first round, all proposed QPIs presented as ‘prescribing rules’ achieved high 15 
scores regarding validity, importance and feasibility (median  ≥ 7/10 without disagreement, 16 
except one with median feasibility of 6.5). No rule was eliminated and three new rules were 17 
introduced. Rules were reworded into ‘prescribing indicators’ for the second round, which 18 
resulted in 35 indicators being accepted and two indicators being eliminated. Seven drug-drug 19 
interactions, all of which received high scores in the first round, were also included in the final 20 
set of QPIs. 21 
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Conclusion: Forty-two QPIs were nominated for use in Australian general practice, based on 22 
their validity, importance and feasibility. If implemented in practice, these QPIs have the 23 
potential to assist in efforts to improve the quality and safety of medicines management. 24 
Keywords: general practice, medication-related problem, drugs, quality indicator, prescribing, 25 
quality of care.  26 
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WHAT IS KNOWN ABOUT THE TOPIC? 27 
 Medication-related problems (MRPs) are an important cause of patient harm in Australia 28 
and are increasingly recognised in general practice through clinical audits, medication 29 
reviews and the observations of embedded pharmacists. 30 
 Quality prescribing indicators (QPIs) have been used to identify MRPs that most 31 
significantly affect patient outcomes , and play a vital role in the improvement of quality 32 
and safety in healthcare. 33 
  Globally, QPIs have been developed and are continually used and updated in many 34 
countries, such as the US and UK. 35 
 In Australia, QPIs for general practice were developed by NPS MedicineWise in 2006 but 36 
had no planned review cycle. Therefore, the current QPIs are significantly outdated. 37 
WHAT DOES THIS PAPER ADD? 38 
 This paper introduces an updated and validated list of quality prescribing indicators (QPIs) 39 
for use in Australian general practice. 40 
 The QPIs have the potential to assist in efforts to improve the quality and safety of 41 
medicines management by enabling users to measure and benchmark prescribing 42 
activities. 43 
 The QPIs are ready for use in further research to test their applicability before they are 44 
widely implemented.  45 
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INTRODUCTION  46 
Medication-related problems (MRPs) are an important cause of patient harm, even in highly 47 
developed healthcare systems, such as that existing in Australia. It has been reported that 48 
approximately 2% to 3% of hospital admissions in Australia are medication-related, with around 49 
50% of these being considered preventable (Roughead and Semple 2009).  50 
In general practice, MRPs are increasingly recognised through clinical audits, medication 51 
reviews and the observations of embedded pharmacists (Benson et al. 2018; Harris 2018). In a 52 
2015-16 report of general practice activity, 11.2% of patients had experienced an adverse drug 53 
event (ADE) in the previous 6 months and about 6% of these resulted in a hospital admission 54 
(Britt et al. 2016). Inappropriate prescribing and under-prescribing of therapeutically beneficial 55 
medications appear to be compounded in the elderly and those with common chronic conditions, 56 
such as cardiovascular disease and diabetes. In an Australian community study of older men 57 
aged 74-80 years, the rate of potentially inappropriate prescribing was 49% and the rate of 58 
medication under-utilisation was 57%. In this group, one consequence of under-prescribing of 59 
cardiovascular drugs was an association with an increased risk of cardiovascular events (Beer 60 
et al. 2011). Another study, conducted over a period of 13 years with 251,305 Australians aged 61 
65 years and older, found the rate of patients having inappropriate medication exceeded 40% 62 
annually (Price et al. 2014).  63 
Reducing MRPs is essential for the improvement of quality and safety in healthcare. To 64 
optimise the impact and cost-effectiveness, efforts need to be targeted at MRPs that most 65 
significantly affect patient outcomes. Quality prescribing indicators (QPIs) have been 66 
developed to “measure the performance of health care providers in several key dimensions 67 
related to the appropriate use of drugs” (World Health Organization 1993). Such QPIs can help 68 
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identify gaps, prompt interventions, detect impact of changes and ultimately improve the quality 69 
and safety of practice (Duerden et al. 2011). QPIs could be applied through a cycle of audit and 70 
feedback (Avery et al. 2011; NPS 2006; Spencer et al. 2014). A Cochrane review confirmed 71 
audit and feedback improved professional practice, with a large effect on prescribing, citing an 72 
improvement of 13% (Ivers et al. 2012). Additionally, in Australian general practice, using 73 
indicators for audit and to provide feedback was found to be effective in improving 74 
cardiovascular disease management (Gadzhanova et al. 2013) and the optimal use of metformin 75 
and insulin in diabetes (Gadzhanova et al. 2011). Indicators also have the capacity to reduce 76 
costs in primary care (Meltzer and Chung 2014). However, as the clinical evidence base, health 77 
priorities and available treatments change over time, any existing indicators should be 78 
periodically reviewed and the need for new indicators considered (Kontopantelis et al. 2014; 79 
Meltzer and Chung 2014).  80 
In the United Kingdom, QPIs for general practice have been used for over 4 decades and are 81 
periodically updated (Avery et al. 2011; Duerden et al. 2011; Spencer et al. 2014). Similarly, 82 
other countries, such as Sweden (Fastbom and Johnell 2015) and the USA (The American 83 
Geriatrics Society 2015), also have a process for updating their QPIs. In contrast, the Australian 84 
QPIs developed by NPS MedicineWise (NPS 2006) had no planned review cycle. These 21 85 
QPIs (8 structural and 13 process) are now significantly out of date and this may explain the 86 
current low utilisation rates. Revision of these QPIs may increase their utility and fulfil the goal 87 
of reducing contemporary MRPs. Therefore, our aim was to update and validate QPIs for use 88 
in Australian general practice using the Delphi technique, which has been validated for 89 
determining healthcare quality indicators (Boulkedid et al. 2011). 90 
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METHODS 91 
There were two phases in this study: preparing a preliminary list of potential QPIs (phase one) 92 
and validating the list of potential QPIs using the Delphi technique (phase two). 93 
Preparing a preliminary list of potential QPIs 94 
The list was constructed by reviewing the 2006 NPS MedicineWise indicators and introducing 95 
new indicators based on currently available international indicators (Appendix 1) and 96 
guidelines, and drug-drug interactions. Additionally, four focus group discussions with 97 
Australian GPs and a general practice based-pharmacist were used to identify topics that were 98 
considered to be important to general practice for inclusion into the list of potential QPIs. All 99 
proposed QPIs were compared with current Australian therapeutic guidelines (eTG complete 100 
available at https://tgldcdp.tg.org.au/etgcomplete) and recent international literature. 101 
Subsequently, the research team, which consisted of four experienced pharmacists and one GP, 102 
modified or eliminated indicators that were considered irrelevant to current practice in 103 
Australia. 104 
Available international indicators were identified through a systematic search of the PubMed 105 
and Embase databases. Search terms were (inappropriate prescribing OR inappropriate 106 
prescription OR inappropriate prescriptions OR inappropriate medication OR inappropriate 107 
medications) AND (scale OR scales OR instruments OR indicator OR indicators OR tool OR 108 
tools OR toolkit OR toolkits OR criteria). The search was limited from 01/01/2003 to 109 
15/04/2017, to English articles and applicable to human subjects aged 65 years old or older. 110 
This narrowed the search to the population most susceptible to adverse events with drugs. 111 
Articles that described criteria to assess hazardous or inappropriate prescribing and articles 112 
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describing updated versions of published indicators were included. Exclusion criteria were 113 
articles describing indicators for a specific disease or a healthcare setting other than general 114 
practice. 115 
Drug-drug interaction indicators were also selected from these international sources, as well as 116 
three other published lists of drug interactions (Appendix 2). The research team identified the 117 
interactions that were included in most of the sources and in accordance with ADEs reported in 118 
an Australian study (Parameswaran Nair et al. 2017).  119 
Validating the potential QPIs list  120 
A group of experts was recruited via personal invitation and advertisements in healthcare 121 
professional newsletters, to help validate the proposed QPIs. The final expert panel comprised 122 
four GPs, four pharmacists and one clinical pharmacologist from Australia, and one clinical 123 
pharmacologist from New Zealand. They were selected based on peer recommendations, 124 
membership of the Australasian Pharmaceutical Science Association (APSA) and/or 125 
Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists 126 
(ASCEPT), and having at least 5 years of clinical experience with a practical understanding of 127 
the general practice context. Some of these experts also had previous experience in indicator 128 
development and quality measurement.  Selection of panel members also sought to ensure 129 
variation in gender and distribution between urban and rural areas. Information sheets were 130 
provided to, and consent forms obtained from, panel participants. 131 
The validation process was conducted using the Delphi technique, a communication method to 132 
achieve a consensus of opinion through a series of questionnaire rounds with an anonymised 133 
summary of the group’s responses fedback after each round. The technique was chosen because 134 
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it does not require face-to-face meetings, which was more practical than either the 135 
RAND/UCLA or nominal group techniques, due to the cost and geographic distribution of our 136 
participants (Campbell et al. 2002).  137 
The process was a two-round survey, conducted online using LimeSurvey. In the first round, 138 
proposed QPIs were presented as ‘prescribing rules’ (Table 1). Each panellist rated these rules 139 
for their validity, importance and feasibility of measurement. Free-text comments were also 140 
allowed in this round, to explore panellists’ viewpoints on the rules. In the second round, the 141 
‘prescribing rules’ were converted into ‘indicators’ (Table 1). Feedback from the previous 142 
round’s responses (represented as mean, median and frequency distribution) was attached and 143 
the panellists were asked to reflect on this information before rating the indicators. Each 144 
indicator was rated for their validity and feasibility. A Likert scale of 1 = inappropriate to 10 = 145 
appropriate was used in both rounds. Table 1 presents the definitions of ‘prescribing rule’, 146 
‘indicator’, rating criteria and an example of a conversion from prescribing rule to indicator. 147 
We determined in advance that two rounds would likely be sufficient as in most published 148 
studies consensus is reached after two rounds and too many rounds may exhaust participants 149 
and decrease the response rate (Keeney et al. 2011). For any QPIs that did not reach consensus 150 
after two rounds, the research team proposed internal discussion until a consensus was reached.  151 
9 
 
Table 1: Definition of prescribing rule, indicator and rating criteria. 152 
Definition of ‘prescribing rule’ and ‘indicator’ 
 Definition 
Prescribing rule A rule is an evidence based statement that guides a particular prescribing 
action. 
Indicator An indicator is a measure of quality presented as percentages of observed 
prescribing actions in a sample of clinical encounters 
Example of converting from prescribing rule to indicator: 
- Prescribing rule: ‘Prescribe pneumococcal vaccine at least once for patients aged more than 65 
years’. 
- Indicator: ‘Percentage of patients older than 65 years who are NOT prescribed pneumococcal 
vaccine’. 
Definition of rating criteria 
 Definition 
Validity An indicator is VALID if it measures a real medication-related problem (i.e. it is 
definitive, with well-accepted evidence). 
Importance An indicator is IMPORTANT if it measures a prevalent problem in general 
practice, and by addressing it could improve quality and safety. 
Feasibility An indicator is FEASIBLE if the extent of the problem can be easily measured 
(e.g. by using data extracted from GPs' clinical software). 
Data analysis and defining consensus 153 
Data were analysed using SPSS version 23 (Armonk, NY: IBM Corp.). Rating scores were 154 
summarised using descriptive statistics, such as means, medians, standard deviations and 155 
percentile. Free-text comments were optional and were evaluated by the research team on a case 156 
by case basis. 157 
The ratings were classified into three levels: appropriate, uncertain and inappropriate, as below. 158 
A consensus was reached when the indicator was rated as appropriate or inappropriate, with 159 
indicators rated as appropriate being included in the final list and indicators rated as 160 
inappropriate being eliminated. A consensus was not reached when the indicator was rated as 161 
uncertain, which was re-rated in the second round or discussed internally by the research team.  162 
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Appropriate: median score >= 7 and less than one-third of respondents rating the 163 
indicator within the 1-3 range. 164 
Inappropriate: median score <= 3 and less than one-third of respondents rating the 165 
indicator within the 7-10 range. 166 
Uncertain: 3 < median score < 7, OR median score >= 7 (or <= 3) and one-third 167 
or more of respondents rating the indicator within the 1-3 range (or 7-10 range).  168 
RESULTS 169 
The systematic search identified 2,260 articles (1,198 from PubMed and 1,062 from Embase). 170 
Removal of duplicates, and title and abstract screening resulted in 120 relevant articles. Full-171 
text screening resulted in 14 final sets of international prescribing indicators. These sets are 172 
listed in Appendix 1. 173 
The response rate from the panel was 100% in the first round and 90% (one pharmacist dropped 174 
out) in the second round. In the first round, there were 31 proposed prescribing rules; nine were 175 
derived from the original NPS MedicineWise indicators and 22 were derived from international 176 
indicators. All prescribing rules were regarded by the panel as valid and important for use as 177 
QPIs (median score ≥ 7 with less than one-third of respondents rating the indicator within the 178 
1-3 range). All rules also reached consensus with high scores regarding feasibility, except one 179 
regarding inhaled corticosteroids for patients with chronic obstructive pulmonary disease 180 
(COPD), that was rated uncertain (median = 6.5) (Table 2). This rule was kept for re-rating in 181 
the second round.  In short, no prescribing rule was eliminated after first round. 182 
In preparation for the second round, the prescribing rules were reworded into ‘indicators’. One 183 
prescribing rule was considered lengthy and complex, and so was separated into four indicators, 184 
to improve clarity. Three new indicators were also recommended by the panel and added to the 185 
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list. This resulted in 37 indicators at the entry of the second round (Figure 1). In this round, 35 186 
indicators reached consensus with high scores regarding validity and feasibility (median score 187 
≥ 7 with less than one-third of respondents rating the indicator within the 1-3 range). There was 188 
one indicator that did not reach consensus for validity and one indicator that did not reach 189 
consensus for feasibility (Table 2) and both of these were then eliminated by the research team.   190 
There were also seven prescribing rules regarding drug-drug interactions. All of them reached 191 
consensus with high scores in all three aspects (median score ≥ 7) in the first round. These were 192 
all accepted for inclusion in the final set of QPIs without changes.  193 
Free-text comments revealed some concerns regarding the feasibility of some QPIs (Table 4). 194 
Additionally, one panellist commented that it would be easier to implement QPIs if they were 195 
simplified to avoid patient subgroups, e.g. measure patients taking anticholinergics rather than 196 
patients with dementia taking anticholinergics.  197 
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Figure 1: Flowchart illustrating validating process. 198 
The final QPIs, comprising 42 indicators, are presented in Table 3, with their corresponding 199 
prescribing rules and rating scores through the two rounds.   200 
7 drug-drug 
interactions 
37 prescribing indicators 
31 prescribing rules 
34 prescribing indicators 
(30 rules  30 indicators 
and  
1 rule  4 indicators) 
 
3 new indicators 
added 
35 prescribing indicators 
2 indicators 
eliminated 
Final 42 QPIs 
Round 1 
Round 2 
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Table 2: Eliminated indicators 201 
202 
Indicator 
Round 1 
Median  
(Interquartile Range) 
Round 2 
Median  
(Interquartile Range) 
Validity Importance Feasibility Validity Feasibility 
Percentage of patients with 
osteoporosis, who have been 
prescribed systemic corticosteroids. 
- - - 
8.00* 
(5) 
9.00 
(1) 
Percentage of patients with COPD who 
have been prescribed an inhaled 
corticosteroid when they do NOT have 
asthma/COPD overlap syndrome and 
do NOT have FEV1 ≤50% of predicted 
and repeated exacerbations. 
9.00 
(1.5) 
8.50 
(2) 
6.50 
(4) 
9.00 
(1) 
7.00* 
(4) 
*  one-third or more of respondents rated the indicator within the opposite 1-3 range 
Table 3: Final QPIs with their corresponding prescribing rules and rating scores through two Delphi rounds. 203 
No Indicator Prescribing rule 
Round 1 
Median  
(Interquartile Range) 
Round 2 
Median  
(Interquartile Range) 
V I F V I F 
1 Percentage of patients aged over 65 years who 
have been prescribed two or more drugs with 
anticholinergic effects concomitantly. 
Avoid prescribing two or more drugs with 
anticholinergic effects concomitantly for patients 
aged over 65 years. 
8.00 
(1.75) 
8.00 
(1) 
8.00 
(2) 
8.00 
(1) - 
8.00 
(1) 
2 Percentage of patients aged over 65 years who 
have been prescribed either tricyclic 
antidepressants, antipsychotics with strong 
anticholinergic effects or urological 
antispasmodic agents. 
Avoid prescribing tricyclic antidepressants, 
antipsychotics with strong anticholinergic effects or 
urological antispasmodic agents for patients aged 
over 65 years. 
8.50 
(1.75) 
8.00 
(0) 
9.00 
(1.75) 
9.00 
(1) 
- 
9.00 
(0) 
3 Percentage of patients aged over 65 years with 
extrapyramidal symptoms caused by 
antipsychotics, who have been prescribed 
anticholinergic antiparkinsonian agents. 
Avoid prescribing anticholinergic antiparkinsonian 
agents for patients aged over 65 years to prevent or 
treat extrapyramidal symptoms caused by 
antipsychotics. 
9.00 
(2.5) 
7.50  
(1.75) 
9.00 
(1.5) 
8.00 
(2) 
- 
7.00 
(3) 
4 Percentage of patients aged over 65 years with 
cognitive impairment/dementia, delirium or 
chronic constipation, who have been prescribed 
drugs with strong anticholinergic effects (except 
inhaled anticholinergics). 
Avoid prescribing drugs with strong anticholinergic 
effects (except inhaled anticholinergics) for patients 
aged over 65 years with cognitive 
impairment/dementia, delirium or chronic 
constipation. 
9.00 
(1.75) 
8.00 
(1.75) 
8.00 
(2.5) 
9.00 
(0) 
- 8.00 
(1) 
5 Percentage of patients aged over 65 years with 
lower urinary tract symptoms and/or benign 
prostatic hyperplasia, who have been 
Avoid prescribing drugs with strong anticholinergic 
effects (except urological antispasmodic agents) for 
8.00 
(1.5) 
8.00 
(2.5) 
8.00 
(1.5) 
8.00 
(1) 
- 8.00 
(3) 
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prescribed drugs with strong anticholinergic 
effects (except urological antispasmodic agents 
for lower urinary tract symptoms). 
patients aged over 65 years with lower urinary tract 
symptoms and/or benign prostatic hyperplasia. 
6 Percentage of patients aged over 65 years with 
a history of narrow angle glaucoma, who have 
been prescribed drugs with strong 
anticholinergic effects. 
Avoid prescribing drugs with strong anticholinergic 
effects for patients aged over 65 years with a history 
of narrow angle glaucoma. 
8.00 
(1) 
7.00 
(1) 
7.00 
(1.5) 
8.00 
(1) 
- 
7.00 
(1) 
7 Percentage of patients receiving 
anticholinesterase drugs (donepezil, 
galantamine, rivastigmine), who have been 
prescribed drugs with strong anticholinergic 
effects concomitantly. 
Avoid prescribing anticholinesterase drugs 
(donepezil, galantamine, rivastigmine) and drugs 
with strong anticholinergic effects concomitantly. 
8.50 
(3) 
8.50 
(3.25) 
9.50 
(1) 
8.00 
(2) 
- 9.00 
(2) 
8 Percentage of patients with a non-specific 
URTIa prescribed an antibiotic. 
Avoid prescribing an antibiotic for patients with a 
non-specific URTIa  
 
10.00 
(0.75) 
9.00 
(1) 
9.00 
(2.75) 
10.00 
(1) - 
9.00 
(2) 
9 Percentage of children aged 6 months to 12 
years who had acute otitis media for less than 2 
days without systemic symptoms, prescribed an 
antibiotic. 
Avoid prescribing antibiotics for children aged 6 
months to 12 years who have had acute otitis media 
for less than 2 days without systemic symptoms. 
10.00 
(0.75) 
8.50 
(1.75) 
8.00 
(2) 
10.00 
(1) 
- 
8.00 
(2) 
10 Percentage of cases of non-specific URTIa, 
pharyngitis, tonsillitis, acute otitis media, 
sinusitis or acute bronchitis with prescriptions of 
cephalexin. 
Avoid prescribing cephalexin for non-specific URTIa, 
pharyngitis, tonsillitis, acute otitis media, sinusitis or 
acute bronchitis. 
9.50 
(1.75) 
9.00 
(3.5) 
8.00 
(2.5) 
9.00 
(1) 
- 8.00 
(2) 
11 Percentage of patients with type II diabetes and 
hypertension and any degree of albuminuria 
who are NOT prescribed an ACEI or ARBb. 
 
Prescribe an ACEI or ARB for patients who have 
type II diabetes and hypertension and any degree of 
albuminuriab. 
9.50 
(1) 
9.00 
(2) 
9.50 
(2) 
9.00 
(1) 
- 9.00 
(3) 
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12 Percentage of patients with a history of acute 
coronary syndrome who are NOT prescribed an 
antiplatelet agent (or anticoagulant), statin and 
ACEI or ARB. 
Prescribe an antiplatelet agent (or anticoagulant), 
statin and ACEI or ARB for patients who have had 
acute coronary syndrome. 
10.00 
(1) 
10.00 
(1) 
9.00 
(1) 
9.00 
(1) 
- 
9.00 
(2) 
13 Percentage of patients prescribed an 
antihypertensive agent who are NOT at their 
target blood pressure. 
Patients prescribed antihypertensive therapy should 
achieve target blood pressure. 
9.50 
(2) 
9.00 
(1.75) 
8.50 
(4.25) 
9.00 
(1) - 
7.00 
(2) 
14 Percentage of patients with heart failure with 
reduced ejection fraction (systolic heart failure) 
who are NOT prescribed an ACEI or ARB, and 
a beta-blockerb. 
Prescribe an ACEI or ARB and a beta-blocker for 
patients with systolic heart failure (LVEF < 40%)b. 
 
10.00 
(0.5) 
9.50 
(1.25) 
9.00 
(2.25) 
9.00 
(2) 
- 
9.00 
(2) 
15 Percentage of patients prescribed 
benzodiazepines where continuous usage 
exceeds 4 weeks. 
Avoid prescribing benzodiazepines for more than 4 
weeks. 
9.00 
(2) 
8.00 
(3) 
9.00 
(0) 
9.00 
(1) - 
9.00 
(2) 
16 Percentage of patients with asthma receiving a 
long-acting beta2-agonist who are NOT 
prescribed an inhaled corticosteroid 
concomitantly. 
Avoid prescribing a long-acting beta2-agonist 
without co-prescribing an inhaled corticosteroid for 
patients with asthma. 
9.50 
(1) 
9.00 
(1.5) 
9.00 
(0.75) 
9.00 
(1) 
- 9.00 
(1) 
17 Percentage of patients with chronic atrial 
fibrillation receiving an oral anticoagulant who 
are prescribed antiplatelet agent(s) 
concomitantly. 
Avoid prescribing antiplatelet agent(s) in 
combination with an oral anticoagulant (vitamin K 
antagonist, direct thrombin inhibitor or factor Xa 
inhibitor) for patients with chronic atrial fibrillation. 
10.00 
(1) 
10.00 
(1) 
9.50 
(1) 
9.00 
(1) 
- 9.00 
(3) 
18 Percentage of patients with non-valvular 
chronic atrial fibrillation who are NOT 
prescribed an oral anticoagulant. 
Prescribe an oral anticoagulant (vitamin K 
antagonist, direct thrombin inhibitor or factor Xa 
inhibitors) for patients (without contraindications) 
with non-valvular atrial fibrillation and a CHA2DS2–
VASc score ≥2. 
9.00 
(2) 
9.00 
(1.5) 
9.00 
(1.75) 
9.00 
(1) 
- 9.00 
(1) 
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19 Percentage of patients with moderate to severe 
COPD, who are NOT prescribed a regular 
inhaled long-acting beta-2 agonist or an inhaled 
long-acting muscarinic antagonist. 
Prescribe a regular inhaled long-acting beta-2 
agonist or an inhaled long-acting muscarinic 
antagonist for patients with moderate to severe 
COPD. 
8.00 
(3.75) 
8.00 
(3.5) 
8.50 
(1.75) 
9.00 
(2) 
- 8.00 
(1) 
20 Percentage of patients with mild to moderate 
COPD, who have been prescribed systemic 
corticosteroid as a maintenance therapy. 
Avoid prescribing systemic corticosteroids in one of 
following conditions: 
+ as a maintenance therapy for mild to moderate 
COPD. 
+ as a long-term monotherapy (>3 months) for 
rheumatoid arthritis.      
+ for osteoarthritis (except intra-articular 
corticosteroids for short-term relief of a flare or 
acute deterioration in symptoms) 
+ for patients with osteoporosis. 
9.00 
(1.75) 
9.00 
(0.75) 
9.00 
(2.75) 
7.00 
(2) - 
7.00 
(2) 
21 Percentage of patients with rheumatoid arthritis, 
who have been prescribed systemic 
corticosteroids continuously for more than 3 
months. 
9.00 
(2) 
- 8.00 
(2) 
22 Percentage of patients with osteoarthritis, who 
have been prescribed systemic corticosteroids 
(except intra-articular corticosteroids). 
9.00 
(2) 
- 9.00 
(1) 
23 Percentage of patients with a documented 
history of coronary, cerebral or peripheral 
vascular disease, who are NOT prescribed a 
statin. 
Prescribe a statin as secondary prevention for 
patients with a documented history of coronary, 
cerebral or peripheral vascular disease, unless the 
patient’s status is end-of-life or age is > 85 years. 
10.00 
(1.75) 
9.00 
(2) 
8.50 
(1.75) 
9.00 
(2) 
- 9.00 
(1) 
24 Percentage of patients who are prescribed a 
short-acting muscarinic antagonist and a long-
acting muscarinic antagonist in combination. 
Avoid prescribing a short-acting muscarinic 
antagonist and a long-acting muscarinic antagonist 
in combination. 
9.00 
(2) 
8.00 
(2.5) 
9.50 
(1.75) 
8.00 
(3) - 
9.00 
(2) 
25 Percentage of patients with persistent non-
cancer pain, who are prescribed strong opioids 
as monotherapy. 
Avoid prescribing strong opioids as monotherapy in 
the management of persistent non-cancer pain. 
9.00 
(2) 
9.00 
(1) 
8.00 
(1.75) 
9.00 
(1) - 
8.00 
(1) 
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26 Percentage of patients with osteoarthritis pain 
and taking NSAID for more than 3 months, who 
have NOT tried regular paracetamol. 
Avoid prescribing NSAID for long-term use (>3 
months) for symptom relief of osteoarthritis pain 
where regular paracetamol has not been tried.   
8.50 
(2.5) 
8.50 
(1) 
7.00 
(1.75) 
8.00 
(2) - 
8.00 
(2) 
27 Percentage of patients aged more than 65 
years who are NOT prescribed seasonal 
influenza vaccine annually. 
Prescribe seasonal trivalent influenza vaccine 
annually.    
10.00 
(3.5) 
8.00 
(3.25) 
10.00 
(0.75) 
10.00 
(2) - 
9.00 
(2) 
28 Percentage of patients aged more than 65 
years who are NOT prescribed pneumococcal 
vaccine. 
Prescribe pneumococcal vaccine at least once for 
patients aged more than 65 years. 
9.50 
(1.75) 
8.50 
(2) 
10.00 
(1) 
9.00 
(2) - 
9.00 
(0) 
29 Percentage of patients receiving a long-term 
systemic corticosteroid (>= 3 months), who 
have NOT been prescribed a bisphosphonate. 
Prescribe a bisphosphonate for patients who have 
severe osteopenia or osteoporosis (BMD T-score of 
-1.5 or less) and who are prescribed a long-term 
(>=3 months) systemic corticosteroid at a dose 
equivalent to or greater than prednisolone 7.5 mg 
per day. 
9.00 
(1.75) 
9.00 
(0.75) 
8.00 
(2) 
9.00 
(1) 
- 9.00 
(1) 
30 Percentage of patients with documented 
osteoporosis and/or patients with previous 
history of fracture due to minimal trauma, who 
have NOT been prescribed an anti-resorptive 
agents. 
Prescribe an anti-resorptive agents for elderly 
patients (>= 70 years old) with documented 
osteoporosis (BMD T-score of -2.5 or less) and/or 
patients with previous history of fracture due to 
minimal trauma. 
9.00 
(2) 
8.50 
(1) 
8.00 
(2.5) 
9.00 
(2) 
- 9.00 
(4) 
31 Percentage of patients with heartburn or mild to 
moderate GORD or oesophagitis, who are 
prescribed a PPI at full therapeutic dosage for 
more than 8 weeks. 
Avoid prescribing a PPI at or above full therapeutic 
dosage for more than 8 weeks for patients with 
heartburn or mild to moderate GORD or 
oesophagitis, and whose symptoms have resolved 
(excludes the situation of prophylaxis e.g. when 
using anticoagulation in a patient with a history of 
9.00 
(1.75) 
8.00 
(2) 
9.00 
(1) 
8.00 
(2) 
- 8.00 
(2) 
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gastrointestinal bleeding; or long-term use of 
NSAID) 
32 Percentage of patients with behavioural and 
psychological symptoms of dementia, who are 
prescribed antipsychotic medications. 
Avoid prescribing antipsychotic medications for 
patients with behavioural and psychological 
symptoms of dementia unless symptoms are severe 
and non-pharmacological treatments have failed. 
9.50 
(1.75) 
9.00 
(0.75) 
8.00 
(3.75) 
8.00 
(3) 
- 8.00 
(3) 
33 Percentage of patients with congestive heart 
failure, who have been prescribed NSAIDs or 
COX-2 inhibitors. 
 
- - - 
9.00 
(2) 
9.00 
(2) 
8.00 
(2) 
34 Percentage of patients with low absolute 
cardiovascular risk, who have been prescribed 
statins for primary prevention. 
 
- - - 
8.00 
(3) 
7.00 
(2) 
8.00 
(2) 
35 Percentage of patients taking antipsychotic 
medicines who receive appropriate monitoringc 
for the development of metabolic side effects 
within 1 year. 
 
- - - 
9.00 
(1) 
9.00 
(1) 
8.00 
(1) 
Drug – Drug Interactionsd 
36 ACEI or ARB  Potassium supplement or Potassium-sparing diuretics or Aldosterone antagonist 9.00 
(2.5) 
8.00 
(3.75) 
8.90 
(0.75) 
- - - 
37 ACEI  ARB  9.50 
(2) 
8.50 
(1.75) 
9.30 
(0.75) 
- - - 
38 Beta blocker  Verapamil 9.50 
(1.75) 
10.00 
(1.75) 
9.40 
(1) 
- - - 
39 Diuretic  NSAID  ACEI or ARB (“Triple Whammy”)e 8.00 
(1.75) 
8.50 
(2) 
9.00 
(1.75) 
- - - 
40 NSAID  vitamin K antagonist or direct thrombin inhibitor or factor Xa inhibitors 9.00 
(2.5) 
8.50 
(2.5) 
9.00 
(0) 
- - - 
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41 Lithium  Diuretics or NSAID or ACEI or ARB 8.00 
(1.75) 
7.00 
(1.75) 
9.00 
(0) 
- - - 
42 Concomitant prescription of three or more drugs within the groups of centrally-acting analgesics, 
antipsychotics, antidepressants and/or benzodiazepines 
8.50 
(1.75) 
8.00 
(1) 
9.00 
(0) 
- - - 
a Non-specific URT includes patients with the common cold and rhinosinusitis. 204 
b Exclude patients with contraindication to ACEI/ARB or beta-blocker. 205 
c Appropriate monitoring includes waist circumference, weight and blood pressure, serum lipid measurements and fasting blood glucose. 206 
d Interaction between two groups of drugs or drug classes is presented as “group 1  group 2”. 207 
e Triple Whammy: a drug interaction between three groups of drugs, that can result in acute renal failure. 208 
V = Validity, I = Importance, F = Feasibility. 209 
ACEI = angiotensin-converting-enzyme inhibitor; ARB = angiotensin II receptor blocker; NSAID = nonsteroidal anti-inflammatory drug; BMD = 210 
bone mineral density; COPD = chronic obstructive pulmonary disease; FEV-1 = forced expiratory volume in 1 second; GORD = gastro-211 
oesophageal reflux disease; URTI = upper respiratory tract infection. 212 
Table 4: Feasibility concerns from the first round’s comments 213 
1) Poor documentation of drugs and laboratory tests. 
2) Lack of coding for diagnoses and drugs.  
3) Difficulty in determining indications for some drugs (e.g. systemic corticosteroids).  
4) Difficulty in determining duration of symptoms (e.g. gastroesophageal reflux).  
5) Problems tracking medicines purchased over-the-counter. 
6) Difficulty in measuring the practice of multiple clinicians and/or in multiple settings.  
 214 
DISCUSSION 215 
Our study produced a list of 42 QPIs for use in Australian general practice. The QPIs cover a 216 
wide range of contemporary prescribing areas and problems (e.g. anticholinergic burden, 217 
cardiovascular disease, asthma, osteoporosis), as well as several important drug-drug 218 
interactions. They were verified for their validity, importance and feasibility in general practice 219 
by an expert panel of stakeholders (GPs, pharmacists and clinical pharmacologists). 220 
Indicators to assess appropriateness of prescribing have been developed in many countries 221 
(Kaufmann et al. 2014). Some are notable for their systematic and continuous approach in the 222 
development and updating of data, such as the Beers indicator in the USA (The American 223 
Geriatrics Society 2015) and the STOPP/START indicator in Europe (O'Mahony et al. 2015). 224 
While these tools can be implemented in any settings, a set of indicators specific for general 225 
practice has also been developed and recently updated in the UK (Avery et al. 2011; Spencer et 226 
al. 2014). In Australia, a set of Quality Use of Medicines Indicators for the hospital setting was 227 
updated in 2014 (ACSQHC and NSW Therapeutic Advisory Group 2014) while the QPIs for 228 
general practice have not been updated since their original development in 2006. Our work is, 229 
therefore, in line with international and local attempts to build and maintain a contemporary 230 
tool to assist in quality and safety improvement initiatives.  231 
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Our QPIs for the general practice setting were similar to that determined, using similar 232 
methodology, in a recent UK general practice study (Spencer et al. 2014). In both studies there 233 
was an emphasis on indicators related to specific conditions (namely cardiovascular, 234 
respiratory, musculoskeletal and neurological conditions), on drug interactions and laboratory 235 
measurement to detect harm. In our study there was more focus on indicators related to 236 
anticholinergc load and the elderly. However, the similarities suggest that such indicators might 237 
apply to primary care globally.  238 
A strength of our study was that we developed a list of QPIs with high validity, based on 239 
international indicators, recent guidelines, literature and expert opinion. Although our QPIs 240 
gained high rates of consensus in feasibility, free-text comments revealed that it could be 241 
difficult to routinely implement some QPIs in practice. For example, paracetamol can be 242 
purchased over-the-counter, so it is difficult to track if patients with osteoarthritis had tried it 243 
before they had been prescribed a long-term NSAID. Nevertheless, the high rating scores 244 
indicate an optimism from the panel for implementation of these QPIs in the future. 245 
Our study has some limitations. We limited our literature search to the elderly so valuable 246 
indicators specific to younger patient groups may have been missed. However, this was 247 
countered by incorporating disease topics related to the younger population through the 248 
qualitative focus group discussions and from reviewing the old NPS MedicineWise indicators. 249 
Secondly, we did not hold a formal discussion process between rounds. This was because 250 
consensus was reached in nearly all cases after the first round. While this could technically have 251 
been the end-point of the survey, the second round augmented panellists’ opinion, hence our 252 
final result. However, for the reproduction of research method, we highlighted standard 253 
feedback with group results, comments and individual scores compared with group averages 254 
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(Boulkedid et al. 2011). Thirdly, characteristics of the panellists, such as their expertise, scope 255 
of practice and experience, may affect the result. Although we addressed these in selection 256 
criteria in accordance with guidelines and standard methodology, there is no universal ‘gold 257 
standard’ for recruiting panellists. Lastly, only one out of four pharmacists in the panel was a 258 
pharmacist working in a general practice. Nevertheless, the other pharmacists have a long-term 259 
experience working closely with general practice and one pharmacist of the research team is 260 
also a general practice pharmacist. This ensured relevant expertise of the panel. 261 
Our QPIs enable users (GPs, pharmacists or other stakeholders) to measure and benchmark 262 
prescribing activities. They serve two main functions: (1) to help identify potential MRPs at an 263 
individual practice level, and hence prompt action to change and improve; and (2) to compare 264 
performance over time, e.g. before and after an improvement initiative is implemented. 265 
However, before the QPIs can be implemented widely, a study to test their applicability should 266 
be conducted.  Due to limited resources in general practice and risk of indicator overload, 267 
initially focussing on indicators considered high risk is recommended in such field trials. The 268 
increasing use, and acceptance of, practice-embedded community pharmacists in Australia is 269 
an essential step in achieving active utilisation of prescribing indicators and should be 270 
considered in future studies.  271 
 272 
CONCLUSION 273 
This study generated 42 contemporary QPIs for use in Australian general practice, based on 274 
their validity, importance and feasibility. Using them as a benchmark in audit and feedback 275 
could help improve the quality and safety of prescribing in primary care.  276 
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APPENDIX 1 
International indicators identified by systematic search 
 
No Indicators Year introduced, 
Country of origin 
Description 
1 Beers indicator [1] 
 
 
2015, USA 
 
 
Lists of potentially inappropriate drug that should be avoided or use with caution in people 
aged 65 years or older.   
The lists are categorized as (1) drugs to avoid in general, (2) drugs to avoid with specific 
diseases/syndromes, (3) drugs to be used with caution, (4) non-anti-infective drugs that 
require dose adjustment based on kidney function and (5) non-anti-infective drug-drug 
interaction  
2 ACOVE indicator [2] 
 
 
2006, USA 
 
 
The set is to access care for “vulnerable elders”, who are at higher risk of mortality or 
functional decline over a period of 2 years. 
There are 392 indicators divided in 26 conditions, covering 4 domains of care (screening 
and prevention, diagnosis, treatment, and follow-up and continuity). 
3 Basger’s indicator [3, 4] 2008, Australia A list of 41 prescribing indicators for Australian elders aged >= 65 years. 
4 Laroche’s indicator [5] 2007, France A list of 34 medications, classified into 29 drugs/ drug class to be avoided in all people 
aged >= 75 years, and 5 drugs to be avoided in specific medical conditions.  
5 Norwegian General Practice 
criteria (NORGEP) [6] 
2009, Norway A list of 36 criteria to assess inappropriate prescription in general practice for people aged 
>= 70 years. The list is divided into 21 inappropriate single drugs and drug dosages, and 
15 inappropriate drugs combinations. 
6 Screening Tool of Older Persons' 
potentially inappropriate 
Prescriptions (STOPP), and 
Screening Tool to Alert doctors to 
Right Treatment (START) [7]  
 
 
2015, Europe 
 
 
A list of 80 indicators to assess potentially inappropriate prescribing   
(STOPP) and a list of 34 indicators to identify prescribing omission in elderly patient aged 
>= 65 years old (START). Indicators in both lists are classified according to physiological 
systems. 
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7 EU(7)-PIM list [8] 2015, Europe A list of 282 medications from 34 therapeutic groups to be used as a screening tool to 
identify potentially inappropriate medication for older people. 
8 Austrian indicator [9] 2012, Austria A list of 73 drugs to be avoided in geriatric patients due to lack of evidence and/or 
unfavourable risk-benefit profile. 
9 Fit for The Aged list (FORTA) [10] 2015, Germany A list of long-term and most frequently used medications for older patients, which includes 
273 drugs belonging to 29 diagnoses/ indication. The drugs are labelled as A 
(indispensable), B (beneficial), C (questionable) or D (avoid) according to evidence of 
safety and efficacy and appropriateness for older patients.   
10 Ghent Older People’s 
Prescriptions community 
Pharmacy Screening (GheOP3S) 
tool [11] 
2016, Belgium A list of 83 drugs/drug classes to be used as a screening tool in community pharmacy to 
identify potentially inappropriate prescribing in older patients.  
The list is divided into 5 parts: (1) potentially inappropriate drugs, independent of 
diagnosis; (2) potentially inappropriate drugs, dependent on diagnosis; (3) potential 
prescribing omissions; 
(4) drug– drug interactions and (5): general care-related items in the community 
pharmacy. 
11 Lindblad’s indicator [12] 2006, USA A list of 28 important drug-disease interaction that cause harmful clinical impact in 
patients aged >=65 years. 
12 Maio’s indicator [13] 2010, Italy A list of 23 inappropriate medications for elder aged >=65 years, which is classified into: 
17 drugs that should be always avoided, 3 drugs that are only appropriate in certain 
circumstances, and 3 drugs that have some indications but are often subject to 
inappropriate use. 
13 The PRISCUS list [14] 2010, Germany A list of 83 drugs in 18 drug classes that are potentially inappropriate for elderly patients. 
Precautions when these drugs are used was also provided. 
14 Shrank’s quality-of-care indicators 
[15] 
2006, USA One hundred thirty-three quality indicators were derived from RAND’s Quality Assessment 
Tools Systems and validated. The indicators were used to assess four domains of 
prescribing: appropriate medication prescribing, avoidance of inappropriate medications, 
medication monitoring, and medication education and documentation. 
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